Top Stock Movers – March 31, 2026
Tuesday, March 31, 2026
/
No Comments
U.S. stocks staged a powerful rebound Tuesday, with investors betting that tensions in the Middle East could ease, but the surge wasn’t enough to rescue what has been the market’s weakest quarter in years.The Dow Jones Industrial Average soared more than 1,100 points, while the S&P 500 and Nasdaq jumped 2.9% and 3.8%, respectively. Despite the strong finish, all three major indexes ended the first quarter in the red, weighed down by volatility tied to the ongoing Iran conflict and rising energy prices.
🚀 Top Stock Winners
Apellis Pharmaceuticals (APLS)
Apellis shares more than doubled up 135% after agreeing to be acquired by Biogen in a deal valued at $5.6 billion, making it one of the day’s most dramatic movers.
Marvell Technology (MRVL)
Marvell led the market higher, surging nearly 13% after announcing a major partnership with Nvidia, including a $2 billion investment. The deal strengthens Marvell’s role in AI infrastructure and sent strong bullish signals across the semiconductor space.
Nvidia (NVDA)
Shares of the AI chip giant climbed 5.6% on the back of the Marvell deal, reinforcing its dominance in next-generation computing and data center growth.
Meta Platforms (META)
Meta was the standout among big tech, jumping 6.7% as investors piled back into growth stocks following recent weakness.
Snap (SNAP)
Snap skyrocketed 15% after activist investor Irenic Capital revealed a stake and outlined a turnaround plan. The proposal includes restructuring initiatives and a sharper focus on AI-driven advertising.
📉 Top Stock Losers
McCormick & Co. (MKC)
Shares fell over 6% after announcing a major merger with Unilever’s food division. Investors appeared cautious about integration risks and deal structure.
Unilever (UL)
Unilever dropped about 5% on the same news, as markets digested the implications of the newly formed $65 billion food conglomerate.
Constellation Energy (CEG)
The stock slid 6% after issuing weaker-than-expected earnings guidance, raising concerns about future profitability.
Biogen (BIIB)
Despite acquiring Apellis, Biogen shares declined 4.5%, reflecting investor skepticism over the cost and near-term earnings impact of the deal.
